Müllerian adenosarcoma (MA) is a rare malignant tumor of the female reproductive system. Owing to the limited number of clinical cases and the absence of characteristic clinical manifestations, its clinical …
Angiogenesis plays a critical role in the progression of endometriosis, with enhanced glycolysis accelerating pathological angiogenesis. Prior research has identified a central role for N6-methyladenosine (m6A) modification in regulating glycolytic …
To investigate the mechanisms by which Shaofu Zhuyu decoction (SFZYD, ) modulates fibrosis in a mouse model of endometriosis.
Endometriosis and irritable bowel syndrome (IBS) are chronic pain disorders that frequently coexist and share key pathophysiological features, including neuroinflammation, visceral hypersensitivity, peripheral sensitization, and central sensitization. Emerging evidence suggests …
Unexpected Diagnosis of Uterine Adenosarcoma With Sarcomatous Overgrowth After Hysteroscopic Polypectomy for a Presumed Endometrial Polyp Cureus
Cervico-vaginal atresia is a rare entity, difficult to diagnose and treat, with a higher rate of complications. It is classified as type 1b mullerian anomaly per ASRM and subclass C4 …
We present the rare case of a 29-year-old patient with uterine adenosarcoma who received fertility-sparing treatment, subsequently conceived spontaneously, and gave birth to a healthy infant.
Extrauterine presentation of Mullerian adenosarcoma is rare and thought to either arise from endometriosis or from spread from a primary uterine or ovarian origin. When accompanied by sarcomatous overgrowth, particularly …
Vulvar lichen sclerosus (VLS) is a chronic condition. If untreated, it may lead to anatomical modifications, including introital stenosis, which may impact sexual function and quality of life. First line …
Endometriosis (EMs) is a chronic inflammatory disease characterized by ectopic growth of endometrial-like tissues. N6-methyladenosine (m6A) modification regulates diverse cellular processes, yet its role in EMs remains unclear. Here, we …